Evidence map›Paper›PMID 35092389›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Effects of Vitamin E on Doxorubicin Cytotoxicity in Human Breast Cancer Cells in Vitro.

Mohadeseh Ahmadi, Akbar Hedayatizadeh-Omran, Reza Alizadeh-Navaei, Majid Saeedi, Ehsan Zaboli, Omolbanin Amjadi, Hamidreza Kelidari, Zahra Besharat

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mohadeseh AhmadiGastrointestinal Cancer Research Center, Non-Communicable Disease Institute, Mazandaran University of Medical Science, Sari, Iran.ORCID 0000-0002-8010-6643
Akbar Hedayatizadeh-OmranGastrointestinal Cancer Research Center, Non-Communicable Disease Institute, Mazandaran University of Medical Science, Sari, Iran.
Reza Alizadeh-NavaeiGastrointestinal Cancer Research Center, Non-Communicable Disease Institute, Mazandaran University of Medical Science, Sari, Iran.ORCID 0000-0003-0580-000X
Majid SaeediDepartment of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0000-0003-2617-9961
Ehsan ZaboliGastrointestinal Cancer Research Center, Non-Communicable Disease Institute, Mazandaran University of Medical Science, Sari, Iran.ORCID 0000-0003-4009-717x
Omolbanin AmjadiGastrointestinal Cancer Research Center, Non-Communicable Disease Institute, Mazandaran University of Medical Science, Sari, Iran.ORCID 0000-0002-1328-6285
Hamidreza KelidariDepartment of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0000-0002-5840-7423
Zahra BesharatGastrointestinal Cancer Research Center, Non-Communicable Disease Institute, Mazandaran University of Medical Science, Sari, Iran.ORCID 0000-0002-0582-0417
Mazandaran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to evaluate in vitro synergistic anticancer effect of doxorubicin combined with Vitamin E.

methodsThe MTT assay was utilized to assess the cytotoxicity of Vitamin E and vitamin E combined with doxorubicin and vital activities of SKBR3, MDA-MB-231, and HFF cells over a 24-hour incubation period. In addition, the antioxidant properties of these interventions and the decrease of reactive oxygen species (ROS) content caused by the treatment were evaluated.

resultsThe antiproliferative effect of doxorubicin increased significantly in combination with vitamin E (Doxcorobicin 2µM vs. Vitamin E 120µM, P=0.000). Despite reducing cell ROS content due to vitamin E treatment, the combination of vitamin E and doxorubicin showed no significant synergistic effect (Doxcorobicin 2µM vs. Vitamin E 120µM, P=0.998).

conclusionThis study indicated that the doxorubicin-vitamin E treatment reduced the viability of breast cancer cells with the minimum side effects on normal cells. In addition, the high dosage of vitamin E intensified the cytotoxicity of doxorubicin.

Indexed as

Antineoplastic AgentsAntioxidantsBreast NeoplasmsCell Line, TumorCell SurvivalDoxorubicinDrug SynergismDrug Therapy, CombinationFemaleHumansReactive Oxygen SpeciesVitamin EAntineoplastic AgentsAntioxidantsDoxorubicinReactive Oxygen SpeciesVitamin EAntioxidantbreast cancerdoxorubicinVitamin E

Identifiers

PMID35092389
PMCPMC9258666
OpenAlexW4210271809

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.